Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:COLL NASDAQ:WVE NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.06-1.1%$4.71$3.97▼$9.18$284.48M1.54400,148 shs604,382 shsCOLLCollegium Pharmaceutical$34.63+0.8%$33.96$29.08▼$50.79$1.12B0.74484,718 shs175,965 shsWVEWAVE Life Sciences$5.91+1.6%$6.78$5.02▼$21.73$1.14B-1.334.21 million shs1.17 million shsXERSXeris Biopharma$6.90-0.4%$6.18$4.30▼$10.08$1.19B0.781.83 million shs923,954 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics+1.74%-3.87%-13.14%-14.23%-53.20%COLLCollegium Pharmaceutical-1.32%+5.05%-3.78%-0.46%+15.66%WVEWAVE Life Sciences+2.65%-4.60%-14.43%-55.38%-19.19%XERSXeris Biopharma+3.28%+12.68%+10.70%+26.92%+58.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.06-1.1%$4.71$3.97▼$9.18$284.48M1.54400,148 shs604,382 shsCOLLCollegium Pharmaceutical$34.63+0.8%$33.96$29.08▼$50.79$1.12B0.74484,718 shs175,965 shsWVEWAVE Life Sciences$5.91+1.6%$6.78$5.02▼$21.73$1.14B-1.334.21 million shs1.17 million shsXERSXeris Biopharma$6.90-0.4%$6.18$4.30▼$10.08$1.19B0.781.83 million shs923,954 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics+1.74%-3.87%-13.14%-14.23%-53.20%COLLCollegium Pharmaceutical-1.32%+5.05%-3.78%-0.46%+15.66%WVEWAVE Life Sciences+2.65%-4.60%-14.43%-55.38%-19.19%XERSXeris Biopharma+3.28%+12.68%+10.70%+26.92%+58.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.44Hold$14.00246.11% UpsideCOLLCollegium Pharmaceutical 2.67Moderate Buy$57.5065.32% UpsideWVEWAVE Life Sciences 2.87Moderate Buy$26.41348.04% UpsideXERSXeris Biopharma 2.43Hold$10.8057.32% UpsideCurrent Analyst Ratings BreakdownLatest BCYC, WVE, COLL, and XERS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026WVEWAVE Life Sciences New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.006/11/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026BCYCBicycle Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/20/2026WVEWAVE Life Sciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$13.00 ➝ $14.005/19/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $13.005/11/2026XERSXeris Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/4/2026WVEWAVE Life Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $24.004/30/2026BCYCBicycle Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/30/2026WVEWAVE Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.004/29/2026WVEWAVE Life Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00 ➝ $15.004/20/2026WVEWAVE Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$72.86M3.88N/AN/A$8.79 per share0.46COLLCollegium Pharmaceutical$780.57M1.44$15.19 per share2.29$9.54 per share3.65WVEWAVE Life Sciences$42.73M26.54N/AN/A$3.10 per share1.90XERSXeris Biopharma$291.85M4.06$0.10 per share66.99$0.08 per share85.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$218.96M-$3.15N/AN/AN/A-344.95%-35.74%-29.54%8/14/2026 (Estimated)COLLCollegium Pharmaceutical$62.87M$2.0417.055.88N/A9.41%95.18%16.39%8/6/2026 (Estimated)WVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%7/30/2026 (Estimated)XERSXeris Biopharma$550K$0.06114.4220.19N/A3.81%735.00%3.24%8/6/2026 (Estimated)Latest BCYC, WVE, COLL, and XERS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026COLLCollegium Pharmaceutical$1.52$1.76+$0.24$0.40$184.47 million$193.52 million5/7/2026Q1 2026XERSXeris Biopharma-$0.0027$0.01+$0.0127$0.01$79.83 million$83.13 million4/30/2026Q1 2026BCYCBicycle Therapeutics-$0.6209-$0.87-$0.2491-$0.87$7.50 million$0.89 million4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 million3/18/2026Q4 2025BCYCBicycle Therapeutics-$1.00-$0.29+$0.71-$0.29$7.08 million$47.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A12.6612.66COLLCollegium Pharmaceutical2.471.711.62WVEWAVE Life SciencesN/A11.2611.26XERSXeris Biopharma17.002.121.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%COLLCollegium PharmaceuticalN/AWVEWAVE Life Sciences89.73%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics22.90%COLLCollegium Pharmaceutical1.85%WVEWAVE Life Sciences24.30%XERSXeris Biopharma4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.81 million53.82 millionOptionableCOLLCollegium Pharmaceutical21032.43 million31.83 millionOptionableWVEWAVE Life Sciences240192.40 million145.65 millionOptionableXERSXeris Biopharma290172.64 million165.13 millionOptionableBCYC, WVE, COLL, and XERS HeadlinesRecent News About These CompaniesJim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma3 hours ago | insidermonkey.comXeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®June 11 at 4:39 PM | businesswire.comXeris to retire $23M of convertible notes through exchange agreementsJune 11 at 2:40 PM | seekingalpha.comXeris Biopharma Announces Private Exchange of Convertible NotesJune 11 at 2:40 PM | finance.yahoo.comXeris Biopharma Announces Debt Reduction via Note ExchangesJune 11 at 7:51 AM | tipranks.comAnalyzing Amylyx Pharmaceuticals (NASDAQ:AMLX) and Xeris Biopharma (NASDAQ:XERS)June 7, 2026 | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Director Sells $91,350.00 in StockJune 6, 2026 | insidertrades.comXeris Biopharma Shareholders Elect Directors and Ratify AuditorJune 5, 2026 | tipranks.comXeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 SharesJune 3, 2026 | insidertrades.comXeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway RightMay 30, 2026 | seekingalpha.comUBS Group AG Reduces Position in Xeris Biopharma Holdings, Inc. $XERSMay 22, 2026 | marketbeat.comShareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) EarningsMay 15, 2026 | finance.yahoo.comXeris Biopharma Quality Draws Market Attention Through Growth SignalsMay 15, 2026 | kalkinemedia.comKVanguard Group Inc. Buys 1,358,760 Shares of Xeris Biopharma Holdings, Inc. $XERSMay 14, 2026 | marketbeat.comResults: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise ProfitMay 9, 2026 | uk.finance.yahoo.comXeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's ChangedMay 8, 2026 | finance.yahoo.comXeris (XERS) Q1 2026 Earnings Call TranscriptMay 7, 2026 | aol.comAXeris Biopharma: Q1 Earnings SnapshotMay 7, 2026 | wtop.comWXeris Biopharma Reports First Quarter 2026 Financial ResultsMay 7, 2026 | finance.yahoo.comXeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comXeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 7, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026These 3 CLO ETFs Target a Niche Corner of the Fixed-Income MarketBy Nathan Reiff | May 31, 2026The Power Grid Is Dying—Is It Time to Buy Its Replacement?By Jeffrey Neal Johnson | May 15, 2026GameStop’s $2 Billion Buyback Sends a Confusing Signal to InvestorsBy Thomas Hughes | June 10, 2026BCYC, WVE, COLL, and XERS Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$4.06 -0.05 (-1.10%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Collegium Pharmaceutical NASDAQ:COLL$34.62 +0.29 (+0.83%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.WAVE Life Sciences NASDAQ:WVE$5.90 +0.10 (+1.64%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.Xeris Biopharma NASDAQ:XERS$6.90 -0.03 (-0.39%) As of 02:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
